Nitric Oxide Services, LLC

08/29/2025

🌟 Publication Announcement 🌟

I’m excited to share that our new research has been published in Anticancer Research! https://ar.iiarjournals.org/content/45/9/3629

Our team including Annette M. Sysel, DVM, MS, Michael Dunphy, Ph.D. and myself... investigated SCC5, a silver-based compound, as a potential alternative to traditional platinum chemotherapy drugs (such as cisplatin). Platinum drugs have saved countless lives, but they are often limited by serious side effects. In contrast, SCC5 showed:

✅ Strong activity against several types of cancer cells (melanoma, colon, ovarian, prostate, and more)

✅ A significantly better safety profile in preclinical testing

✅ Evidence of triggering natural cell death pathways in cancer cells

This work highlights how silver, long known for its healing properties, may play an important role in the future of cancer therapy.

💡 A huge thank you to the reviewers and editorial team for their thoughtful insights, and to the institutions that made this work possible:

Nitric Oxide Services, LLC (Akron, OH)

Bauer Research Foundation(Akron, OH)

Walsh University (North Canton, OH)

And a special tribute to The University of Akron especially Dr. Wiley J. Youngs, whose pioneering work in silver carbene chemistry paved the way for this study.

We are only at the beginning, but this is a promising step forward in developing safer, more effective cancer treatments.

🔗 Read more here: https://ar.iiarjournals.org/content/45/9/3629

Background/Aim: Platinum-based chemotherapeutics remain the standard of care for many solid tumors; however, they have dose-limiting toxicities. Silver(I) N -heterocyclic carbene complexes represent a novel class of metallodrugs with potential anticancer activity and improved tolerability. This stud...

07/14/2025

Congratulations to Dr. Brian Leyshon - Abbott- and Team!

Thrilled to see the late-breaking abstract presented at The European Society for Clinical Nutrition and Metabolism (ESPEN) - : “A Novel Lipid Technology Improves Vitamin D3 Absorption in Healthy Adults”

This innovative study—led by Dr. Brian Leyshon and colleagues from Abbott Laboratories, Walsh University, Nitric Oxide Services, LLC, and the University of Dayton—demonstrates that a new lipid-based formulation (MDGPL) significantly enhances the absorption of vitamin D3 in healthy adults. Notably, the MDGPL technology improved absorption by up to 54% at standard dietary doses, leading to meaningful increases in serum 25(OH)D3 levels.

Given that vitamin D insufficiency remains a global challenge, these findings offer promising solutions for improving nutritional status and health outcomes.

Proud to be part of this collaborative effort and excited to see the impact of these advances on clinical nutrition!

Presented at: ESPEN 2025, Late-Breaking Abstract Session

Authors: Brian J. Leyshon, Steven R. Hertzler, Kelsey F. Scanlon, Michael J. Dunphy, Qi Yao, Joseph A. Bauer, Joseph I. Harper, Lindsay K. Schultz



Link to ESPEN Programme & Abstract:

Explore the ESPEN 2025 Congress Main Programme for a comprehensive overview of cutting-edge clinical nutrition and metabolism sessions.

07/05/2025

🚀 New Publication Alert! 🚀

Looking back on 25+ years since earning my doctorate in biochemistry, if I had to pick one assay that has truly defined my career, it would be the Sulforhodamine B (SRB) assay. This robust, versatile method verified the anticancer activity of a compound I synthesized—nitrosylcobalamin—and laid the foundation for a landmark publication in the JNCI: Journal of the National Cancer Institute.

The SRB assay has been at the core of my teaching and mentoring, helping train countless students at both university and high school levels. It has allowed me to share the excitement of anticancer research with students, educators, and colleagues alike. Special recognition to Dr. Amy Heston, who trained several outstanding students at Walsh University, leading to published studies on the effects of copper and heavy metals on various human cancer cell lines.

I'm proud to share that we have now published a detailed, step-by-step guide to the SRB assay, making it accessible to educators and research labs everywhere. Our hope is that this protocol will empower more teams to screen both natural and synthetic compounds for anticancer activity, expanding the arsenal in the fight against cancer.

Check out our new publication here:
🔗 ScienceDirect: A Versatile Vanadium(III)-Based Chemiluminescence Protocol for Nitric Oxide Metabolite Quantification and NO Release Kinetics https://www.sciencedirect.com/science/article/pii/S2215016125003140?via%3Dihub

Let’s inspire the next generation of cancer researchers and educators—one assay at a time!

04/01/2025

Welcome to Nitric Oxide Services, LLC (NOS) — Your CLIA-Certified Partner in Nitric Oxide Science

Nitric Oxide Services, LLC (NOS) is a premier consulting and research organization dedicated to advancing the science and application of nitric oxide and related biochemical pathways in health, medicine, and exercise science. Our mission is to help clients optimize physiological function, improve clinical outcomes, and drive innovation through nitric oxide-based solutions.

As a CLIA-certified laboratory (CLIA # 36D2321191), we meet the highest federal standards for laboratory quality and compliance. This certification enhances our ability to deliver validated, high-precision nitric oxide (NOx: nitrate and nitrite) biomarker testing, supporting both clinical trials and product development with data you can trust.

Backed by a multidisciplinary team of seasoned researchers, clinicians, and consultants with decades of combined experience, NOS operates at the forefront of nitric oxide science and translational research.

Our laboratory is equipped with:

State-of-the-art analytical instrumentation

Tissue culture facilities

Specialized chemical reactors

CLIA-compliant biomarker testing services

In addition, we have privileged access to the Comparative Medicine Unit (CMU) — a 41,000-square-foot, fully accredited preclinical research facility. The CMU maintains full compliance with USDA regulations and holds an Animal Welfare Assurance from the Office of Laboratory Animal Welfare (OLAW), supporting advanced preclinical studies.

At NOS, we integrate cutting-edge research, regulatory expertise, and clinical trial support to advance the boundaries of nitric oxide science. Whether you are developing medical devices, supplements, or therapeutic interventions, we are here to accelerate your innovation with trusted data and proven results.

At Nitric Oxide Services, we specialize in comprehensive validation of medical devices, supplements, nitric oxide precursors and donors especially within the realm of applications in health and medicine including exercise science. We have worked successfully to advance client projects in the areas o...

04/01/2025

📣 We are officially CLIA-Certified!

Nitric Oxide Services, LLC has been awarded a CLIA Certificate (CLIA # 36D2321191) — a critical milestone that underscores our commitment to delivering high-quality, compliant, and reliable laboratory testing services.

Why does this matter for you?

✔️ CLIA certification ensures that our laboratory meets rigorous federal quality standards for accuracy, reliability, and timeliness of results — giving you confidence in the data that supports your clinical trial.

✔️ We specialize in nitrate, nitrite (NOx), and nitric oxide-based biomarker testing — essential endpoints for trials focused on cardiovascular health, exercise physiology, metabolism, and beyond.

✔️ Our team is ready to support sponsors, CROs, and investigators with customized testing solutions designed to strengthen your research outcomes.

Whether you are launching a new clinical trial or enhancing an existing one, we are here to provide validated, regulatory-compliant assays to meet your needs.

🔗 Contact us today to learn how Nitric Oxide Services, LLC can bring added value to your clinical research.

https://www.nitricoxidelab.com/

At Nitric Oxide Services, we specialize in comprehensive validation of medical devices, supplements, nitric oxide precursors and donors especially within the realm of applications in health and medicine including exercise science. We have worked successfully to advance client projects in the areas o...

04/01/2025

⚖️ FDA’s LDT Rule Struck Down — What Happens Next for Diagnostic Innovation?

The FDA recently lost its attempt to regulate Lab-Developed Tests (LDTs) as medical devices after a federal judge vacated the rule.

For laboratories which already validate tests under ICH M10 and meet CLIA requirements, this ruling highlights a deeper issue:

Are we adding regulations for the sake of control, or are we solving a real problem?

In this blog, I offer a balanced view of: ✅ Why the rule was made
✅ Why the court rejected it
✅ The future of LDTs, innovation, and patient access

This moment matters — for labs, clinicians, and most importantly, patients.

https://thebiochemistknowsbest.com/f/fdas-now-vacated-rule-on-ldts-unnecessary-fix

FDA's Now-Vacated Rule on LDTs: Unnecessary Fix for a Problem That Didn’t Exist?

03/28/2025

Over 25 years ago, I synthesized and patented a molecule called Nitrosylcobalamin (NO-Cbl)—a vitamin B12 analog designed to deliver nitric oxide (NO) therapeutically. Inspired by groundbreaking work by Brouwer et al. (Blood, 1996) and Greenberg et al. (JPET, 1995), who observed natural formation of NO-cobalamin interactions in the body, I sought to create a stable and bioactive compound that harnessed these biochemical interactions.

Today, I'm humbled to see over 20 peer-reviewed studies on NO-Cbl listed in PubMed, the latest of which was just published:

https://pubmed.ncbi.nlm.nih.gov/40150986/

Yet, the journey hasn't been easy. Nitrosylcobalamin sparked controversy among traditional vitamin B12 researchers, especially when I collaborated with renowned B12 expert Dr. Bellur Seetharam. Instead of welcoming innovative approaches, some sought to undermine this new direction—even pushing unsuccessfully to rename the molecule inaccurately to "nitroxylcobalamin."

I've often thought of sharing these behind-the-scenes stories in academia, where collaboration sometimes gives way to rivalry and politics. My experience is not unique; many researchers face similar resistance when challenging established paradigms.

However, seeing my work validated and expanded upon by other researchers gives me renewed energy and hope. I'll continue working diligently to translate these findings into clinical breakthroughs to ultimately improve patient outcomes.

To fellow innovators facing similar battles: keep pushing forward—the science, and those who will benefit from it, depend on your perseverance.

Variations in IF binding between NO-Cbl and OH-Cbl may be attributed to the saturation of binding sites or recognition issues specific to plant-derived IF. This study underscores the potential of NO-Cbl as a targeted therapeutic agent capable of leveraging natural cobalamin uptake pathways. These re...

03/18/2025

We're excited to announce the publication of our latest research study in Frontiers in Bioscience (Elite Edition)!

Our study, titled "Evaluation of the Binding Affinity of Nitrosylcobalamin to Intrinsic Factor as a Predictive Model for Cobalamin Binding Protein Interactions: A Comparative Study with Hydroxocobalamin", explores the binding dynamics of nitrosylcobalamin (NO-Cbl), a promising vitamin B12 analog with potential therapeutic applications, especially in cancer treatment.

🔬 Key Highlights:

We utilized Surface Plasmon Resonance (SPR) to analyze the binding affinity of NO-Cbl and hydroxocobalamin (OH-Cbl) to recombinant human intrinsic factor (IF) derived from plants.
Both compounds demonstrated high binding affinities in the picomolar range, showcasing their potential for targeted therapeutic delivery.

Our data revealed nuanced differences in binding stability and kinetics, important considerations for developing targeted therapeutics leveraging natural cobalamin uptake pathways.

🌱 This work underscores the effectiveness of plant-derived IF as a reliable and scalable model for predicting the biological interactions of cobalamin analogs.

📖 Read the full open-access article here: https://www.imrpress.com/journal/FBE/17/1/10.31083/FBE26810

We're grateful for the collaborative efforts and insightful reviews that helped strengthen this study. Special thanks to our colleagues at Cleveland Clinic and Cobento Biotech for their invaluable contributions.

Let's connect and discuss how NO-based therapies can revolutionize targeted treatment strategies!

Background: Intrinsic factor (IF) is a glycoprotein crucial for cobalamin (vitamin B12) absorption in the human body. This study aimed to evaluate the binding affinity of nitrosylcobalamin (NO-Cbl), a cobalamin analog, to recombinant human IF derived from plants, using hydroxocobalamin (OH-Cbl) as a...

03/08/2025

Enter to win $250 in product! Help Us Name the Future of Beet Juice! 🩸🥕🚀

Exciting things are happening! BaeRyeo Innovation is working to bring the powerhouse beet juice “Cula”—currently a hit in South Korea—to the USA and beyond! 🌎

But before we do, we need your help! 🗳️

🔴 We’re looking for a new name for Cula! 🔴or do we keep the name?

We want a name that reflects the power, health benefits, and vitality of this pure nitric oxide-boosting beet juice.

💡 Participate in our short 5-question survey to help us choose!
https://forms.office.com/r/uPqZ7RZXxs

🎟️ Everyone who completes the survey will be entered into a random drawing to receive ONE CASE of Cula! (a $250 value!)

📢 Attached are three exciting marketing campaign concepts. We’d love your feedback on which direction resonates most!

🔬 Why are we bringing Cula to the U.S.?
Cula is a simple, natural, and powerful beet juice designed to support circulation, endurance, and overall wellness. With our expertise in one-carbon metabolism and nitric oxide research, we’re working to introduce this innovative product to a global audience.

⚡ Join us in shaping the future of beet juice!

Take the survey now and be part of this exciting journey! 🚀🥤
https://forms.office.com/r/uPqZ7RZXxs

12/05/2024

🌟 Congratulations to Shiftwave.co on this incredible milestone! 🌟

We at Nitric Oxide Services, LLC are thrilled to see Shiftwave advancing recovery and wellness with its innovative technology. The recent partnership with the NFLPA, OneTeam Partners, and EXOS underscores its growing impact in the field of health optimization.

Building on our expertise in nitric oxide, we are excited about the opportunity to deliver evidence-based assessments to validate the biochemistry underpinning Shiftwave’s technology.

Through rigorous analysis of nitric oxide signaling and biomarkers, we aim to scientifically substantiate the remarkable health benefits of Shiftwave, paving the way for its continued success.

Here’s to a future of innovation and collaboration, driving performance, recovery, and holistic well-being!



https://www.sportsbusinessjournal.com/Articles/2024/12/04/shiftwave-nflpa-oneteam-partners-exos?fbclid=IwY2xjawG9_BdleHRuA2FlbQIxMAABHXa6v5qVvPeYCKIZn6LJk2KAaQt-H-aeL0HhcooaluYNIWGuK-wI8ulSZw_aem_svyonemR3KEafm7MS5yuzg

Shiftwave uses precise vibration patterns aim to provide stress and pain relief while improving physical recovery, sleep quality and mental focus. The goal of the multi-party, multi-year deal is to drive awareness, help athletes and create commercial opportunities.

11/07/2024

🚀 Exciting Opportunity for Diabetic Foot Ulcer Clinical Trial Participation! 🚀

Nitric Oxide Services, LLC is proud to support our client, NOxy Health Products, in their latest clinical trial to explore innovative nitric oxide-based therapies for patients with non-healing diabetic foot ulcers.

This study aims to advance understanding of nitric oxide’s therapeutic potential in wound healing, circulation improvement, and tissue repair. By participating, patients have the unique opportunity to contribute to groundbreaking research that could lead to improved care options for chronic and acute wounds.

Study Locations

This trial has three active recruitment sites across the United States:

📍 Omaha, Nebraska

Location: SerenaGroup Omaha

Contact: Bennet Rogers, 888-960-1343 ext 1008, brogers@serenagroups.com

Sub-Investigator: Bennet Rogers

📍 Kittanning, Pennsylvania

Location: SACMH Wound Center

Contact: Nicole Schrecengost, 724-543-8536, nschrecengost@serenagroups.com

Sub-Investigator: Nicole Schrecengost

📍 Monroeville, Pennsylvania

Location: SerenaGroup Monroeville

Contact: Laura Serena, 412-212-0123, lserena@serenagroups.com

Sub-Investigator: Laura Serena

For those interested, this is a chance to actively support innovations in healthcare and gain access to advanced therapeutic research.

🌐 Reach out to the contact at your preferred location to learn more about eligibility and participation earn more about eligibility and participation.
https://clinicaltrials.gov/study/NCT06402565?term=NOxy%20health&rank=1 -criteria

10/24/2024

🧠 If you or someone you know is affected by Parkinson's Disease (PD), this blog is a must-read!

🔗 Understanding the Importance of One-Carbon Metabolism https://fl314bauer.com/f/understanding-the-importance-of-one-carbon-metabolism

This blog dives into the critical role of one-carbon metabolism and its potential impact on managing PD symptoms. If you're looking for an inexpensive treatment option that is often overlooked and understated, consider this supplement:

👉 Why Not Natural - Methylcobalamin & Adenosylcobalamin & Hydroxocobalamin & Methylfolate: https://www.amazon.com/Why-Not-Natural-Methylcobalamin-Adenosylcobalamin/dp/B0CBHQP6WR?pd_rd_w=FKStt&content-id=amzn1.sym.4311067e-a9df-4e8a-a5ce-d6836ea1723b&pf_rd_p=4311067e-a9df-4e8a-a5ce-d6836ea1723b&pf_rd_r=K82X88PCFSM98FNARV1Y&pd_rd_wg=m9k9t&pd_rd_r=6940465a-4311-4a89-9f5b-08ac3ab34982&pd_rd_i=B0CBHQP6WR&psc=1&ref_=pd_bap_d_grid_rp_0_1_ec_scp_pd_hp_d_atf_rp_1_t

💊 Take it twice daily or as needed, based on your symptoms and under the guidance of your physician.

Let’s shine a light on effective, affordable solutions for managing Parkinson’s Disease symptoms. 🌟

Why Not Natural Vitamin B12 5000 mcg Supplement with Methylcobalamin, Adenosylcobalamin and Hydroxy B12 complex with Methylfolate 1000 mcg, L-5-MTHF, Made with Organic Spirulina